ESR1 and breast cancer: Therefore, combination analyses between Tel and the CDK4/6 inhibitors abemaciclib (Abe) and palbociclib (Palbo) were performed in a cellular model mimicking the metastatic breast cancer expressing the ERα mutated in the Y residue 537 to S (i.e., Y537S cells) [42].